The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
Open accessAbstract
Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Population Pharmacokinetic and Pharmacodynamic Analysis of Bosutinib
Hsyu, P., Mould, D. R., Abbas, R., & Amantea, M. (2014) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-13-rg-126 · Cited by 21
RetractedFaivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,164
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
Krueger, D. A., Care, M. M., Holland, K., Agricola, K., Tudor, C., Mangeshkar, P., Wilson, K. A., Byars, A., Sahmoud, T., & Franz, D. N. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001671 · Cited by 1,006
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001
Marin, D., Bazeos, A., Mahon, F.-X., Eliasson, L., Milojkovic, D., Bua, M., Apperley, J. F., Szydlo, R., Desai, R., Kozlowski, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3087 · Cited by 909
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205127 · Cited by 769
Larson, R. A., Druker, B. J., Guilhot, F., O'Brien, S. G., Riviere, G. J., Krahnke, T., Gathmann, I., & Wang, Y. (2008) · Blood · doi:10.1182/blood-2007-10-116475 · Cited by 643
Burris, H. A., Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K. L., O'Neil, B., Marcom, P. K., Ellis, M. J., Overmoyer, B., Jones, S. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.584 · Cited by 619
Kumar, R., Knick, V. B., Rudolph, S. K., Johnson, J. H., Crosby, R. M., Crouthamel, M.-C., Hopper, T. M., Miller, C. G., Harrington, L. E., Onori, J. A., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0193 · Cited by 517
Houk, B. E., Bello, C. L., Poland, B., Rosen, L. S., Demetri, G. D., & Motzer, R. J. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1170-y · Cited by 477
Bible, K. C., Suman, V. J., Molina, J. R., Smallridge, R. C., Maples, W. J., Menefee, M. E., Rubin, J., Sideras, K., Morris, J. C., McIver, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70203-5 · Cited by 421
Demetri, G. D., Wang, Y., Wehrle, E., Racine, A., Nikolova, Z., Blanke, C. D., Joensuu, H., & von Mehren, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.4818 · Cited by 401
Holden, S. N., Eckhardt, S. G., Basser, R., de Boer, R., Rischin, D., Green, M., Rosenthal, M. A., Wheeler, C., Barge, A., & Hurwitz, H. I. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi247 · Cited by 304
Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis
Trojano, M., Lucchese, G., Graziano, G., Taylor, B. V., Simpson, S., Lepore, V., Grand’Maison, F., Duquette, P., Izquierdo, G., Grammond, P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048078 · Cited by 238
Yu, H., Steeghs, N., Nijenhuis, C. M., Schellens, J. H. M., Beijnen, J. H., & Huitema, A. D. R. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0137-2 · Cited by 231
Self-citationHouk, B. E., Bello, C. L., Kang, D., & Amantea, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1893 · Cited by 231
Rini, B. I., Melichar, B., Ueda, T., Grünwald, V., Fishman, M. N., Arranz, J. A., Bair, A. H., Pithavala, Y. K., Andrews, G. I., Pavlov, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70464-9 · Cited by 231
LU, J., EPPLER, S., WOLF, J., HAMILTON, M., RAKHIT, A., BRUNO, R., & LUM, B. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.04.007 · Cited by 227
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
Wind, S., Schnell, D., Ebner, T., Freiwald, M., & Stopfer, P. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0440-1 · Cited by 206 · cited 1×
“6 ng/mL in those with only Grade 1–2 rash.(29) A consistent relationship between exposure and response has not been found yet for afatinib.”
Suttle, A. B., Ball, H. A., Molimard, M., Hutson, T. E., Carpenter, C., Rajagopalan, D., Lin, Y., Swann, S., Amado, R., & Pandite, L. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.503 · Cited by 190
Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
Rini, B. I., Schiller, J. H., Fruehauf, J. P., Cohen, E. E. W., Tarazi, J. C., Rosbrook, B., Bair, A. H., Ricart, A. D., Olszanski, A. J., Letrent, K. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2806 · Cited by 181
Therapeutic Drug Monitoring of Everolimus: A Consensus Report
Shipkova, M., Hesselink, D. A., Holt, D. W., Billaud, E. M., van Gelder, T., Kunicki, P. K., Brunet, M., Budde, K., Barten, M. J., SIMONE, P. D., et al. (2016) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000260 · Cited by 141
Rini, B. I., Garrett, M., Poland, B., Dutcher, J. P., Rixe, O., Wilding, G., Stadler, W. M., Pithavala, Y. K., Kim, S., Tarazi, J., et al. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.73 · Cited by 137
Guilhot, F., Hughes, T. P., Cortes, J. E., Druker, B. J., Baccarani, M., Gathmann, I., Hayes, M., Granvil, C. P., & Wang, Y. L. (2012) · Haematologica · doi:10.3324/haematol.2011.045666 · Cited by 134
Larson, R. A., Yin, O. Q. P., Hochhaus, A., Saglio, G. N., Clark, R. E., Nakamae, H., Gallagher, N. J., Demirhan, E., Hughes, T. P., Kantarjian, H. M., et al. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1200-7 · Cited by 108
Lankheet, N. A. G., Kloth, J. S. L., Hooijdonk, C. G. M. G.-V., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.194 · Cited by 106
Boudou, P., Narjoz, C., Golmard, J. L., Thomas‐Schoemann, A., Mir, O., Taïeb, F., Durand, J.-P., Coriat, R., Dauphin, A., Vidal, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042875 · Cited by 104
Shah, N. P., Wang, Roy, A., Hochhaus, A., Kantarjian, & Chen, T. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s42796 · Cited by 100
HLA-B *57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer
Xu, C., Johnson, T., Wang, X., Carpenter, C., Graves, A. P., Warren, L. L., Xue, Z., King, K. S., Fraser, D. J., Stinnett, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2044 · Cited by 98
Wind, S., Schmid, M., Erhardt, J., Goeldner, R.-G., & Stopfer, P. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0091-4 · Cited by 94
Okamoto, I., Kaneda, H., Satoh, T., Okamoto, W., Miyazaki, M., Morinaga, R., Ueda, S., Terashima, M., Tsuya, A., Sarashina, A., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0379 · Cited by 94
Joerger, M., von Pawel, J., Kraff, S., Fischer, J. R., Eberhardt, W., Gauler, T. C., Mueller, L., Reinmuth, N., Reck, M., Kimmich, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw290 · Cited by 91
Menzies, A. M., Ashworth, M. T., Swann, S., Kefford, R. F., Flaherty, K. T., Weber, J. S., Infante, J. R., Kim, K. B., Gonzalez, R. C., Hamid, O., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu529 · Cited by 90
Bouchet, S., Poulette, S., Titier, K., Moore, N. D., Lassalle, R., Abouelfath, A., Italiano, A., Chevreau, C., Bompas, E., Collard, O., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.029 · Cited by 90
Fukudo, M., Ito, T., Mizuno, T., Shinsako, K., Hatano, E., Üemoto, S., Kamba, T., Yamasaki, T., Ogawa, O., Seno, H., et al. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0108-z · Cited by 89
Juraskova, I., Butow, P. N., Bonner, C., Bell, M. L., Smith, A. B., Seccombe, M., Boyle, F. M., Reaby, L., Cuzick, J. M., & Forbes, J. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.144 · Cited by 86
Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib
Ramanathan, S., Jin, F., Sharma, S., & Kearney, B. P. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0304-0 · Cited by 85
Ravaud, A., Urva, S., Grosch, K., Cheung, W. K., Anak, O., & Sellami, D. B. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.022 · Cited by 85
Giles, F. J., Yin, O. Q. P., Sallas, W. M., le Coutre, P. D., Woodman, R. C., Ottmann, O. G., Baccarani, M., & Kantarjian, H. M. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1385-4 · Cited by 83
Fox, P., Balleine, R. L., Lee, C., Gao, B., Balakrishnar, B., Menzies, A. M., Yeap, S. H., Ali, S. S., Gebski, V., Provan, P. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1470 · Cited by 79
Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib
Abbas, R., & Hsyu, P. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0391-6 · Cited by 75
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib
Lankheet, N. A. G., Desar, I. M. E., Mulder, S. F., et al. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13327 · Cited by 74
Singh, N., Kumar, L., Meena, R., et al. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0621-z · Cited by 73
Kobayashi, H., Sato, K., Niioka, T., Miura, H., Ito, H., & Miura, M. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.004 · Cited by 63
Ouellet, D., Kassir, N., Chiu, J., Mouksassi, S., Leonowens, C., Cox, D. S., DeMarini, D. J., Gardner, O., Crist, W. A., & Patel, K. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2993-y · Cited by 61
Funck‐Brentano, E., Alvarez, J., Longvert, C., Abé, E., Beauchet, A., Funck‐Brentano, C., & Saïag, P. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv189 · Cited by 55
Singh, H., Brave, M. H., Beaver, J. A., Cheng, J., Tang, S. W., Zahalka, E. A., Palmby, T. R., Venugopal, R., Song, P., Liu, Q., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1073 · Cited by 54
Kramkimel, N., Thomas‐Schoemann, A., Sakji-Dupré, L., Golmard, J. L., Noé, G., Regnier-Rosencher, E., Chapuis, N., Maubec, E., Vidal, M., Avril, M., et al. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0375-8 · Cited by 53
Bershas, D. A., Ouellet, D., Mamaril-Fishman, D., Nebot, N., Carson, S. W., Blackman, S. C., Morrison, R. A., Adams, J. L., Jurusik, K., Knecht, D., et al. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.053785 · Cited by 52
the Inter-Michinoku Dasatinib Study Group (IMIDAS), Ishida, Y., Murai, K., Yamaguchi, K., Miyagishima, T., Shindo, M., Ogawa, K., Nagashima, T., Sato, S., Watanabe, R., et al. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1968-y · Cited by 50
Zhao, Y., Su, L., Zhang, Y., Zhao, H.-Y., Liao, H., Guo, Y. Q., Shi, Y.-X., Jiang, W., Xue, C., & Zhang, L. (2010) · Medical Oncology · doi:10.1007/s12032-010-9541-0 · Cited by 48
Yamazaki, S. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9436-4 · Cited by 47
Yu, H., Steeghs, N., Kloth, J. S. L., de Wit, D., van Hasselt, J. G. C., van Erp, N. P., Beijnen, J. H., Schellens, J. H. M., Mathijssen, R. H. J., & Huitema, A. D. R. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12550 · Cited by 39
Self-citationThiery-Vuillemin, A., Mouillet, G., Hon, T. N. T., Montcuquet, P., Maurina, T., Almotlak, H., Stein, U., Montange, D., Foubert, A., Nerich, V., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2435-7 · Cited by 37
Hsyu, P., Mould, D. R., Upton, R. N., & Amantea, M. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1998-4 · Cited by 34
Teo, Y. L., Chue, X. P., Chau, N. M., et al. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0349-2 · Cited by 30
Steffens, M., Paul, T., Hichert, V., Scholl, C., von Mallek, D., Stelzer, C., Sörgel, F., Reiser, B., Schumann, C., Rüdiger, S., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.022 · Cited by 25
Cited by
Braal, C. L., Jongbloed, E. M., Wilting, S. M., Mathijssen, R. H. J., Koolen, S. L. W., & Jager, A. (2021) · Drugs · doi:10.1007/s40265-020-01461-2 · Cited by 438
Brüggemann, R. J., Verheggen, R., Boerrigter, E., Stanzani, M., Verweij, P. E., Blijlevens, N. M. A., & Lewis, R. E. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00232-5 · Cited by 67
Feasibility of and patients’ perspective on nilotinib dried blood spot self-sampling
Boons, C. C. L. M., Timmers, L., Janssen, J. J. W. M., Swart, E. L., Hugtenburg, J. G., & Hendrikse, N. H. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02640-1 · Cited by 36
Adiwidjaja, J., Boddy, A. V., & McLachlan, A. J. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03266-y · Cited by 14
Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
Tridente, G., Jana, A., Nath, A., & Ashraf, G. M. (2023) · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders · doi:10.1016/b978-0-443-18677-6.00015-4 · Cited by 8
Metadata
- Authors
- Verheijen, R. B., Yu, H., Schellens, J. H. M., Beijnen, J. H., Steeghs, N., & Huitema, A. D. R.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2017-09-07
- Volume
- 102
- Issue
- 5
- Pages
- 765-776
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2735359179
- Cited by
- 278
- References
- 58
- FWCI
- 22.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.